142 related articles for article (PubMed ID: 30909892)
1. Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
Blair CM; Walsh NM; Littman BH; Marcoux FW; Baillie GS
BMC Cancer; 2019 Mar; 19(1):266. PubMed ID: 30909892
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-8A binds to and regulates Raf-1 kinase.
Brown KM; Day JP; Huston E; Zimmermann B; Hampel K; Christian F; Romano D; Terhzaz S; Lee LC; Willis MJ; Morton DB; Beavo JA; Shimizu-Albergine M; Davies SA; Kolch W; Houslay MD; Baillie GS
Proc Natl Acad Sci U S A; 2013 Apr; 110(16):E1533-42. PubMed ID: 23509299
[TBL] [Abstract][Full Text] [Related]
3. PDE8 controls CD4
Basole CP; Nguyen RK; Lamothe K; Vang A; Clark R; Baillie GS; Epstein PM; Brocke S
Cell Signal; 2017 Dec; 40():62-72. PubMed ID: 28851628
[TBL] [Abstract][Full Text] [Related]
4. Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance
Poudel M; Kim G; Bhattarai PY; Shin S; Zaraei SO; Oh CH; Choi HS
Anticancer Res; 2022 Jun; 42(6):2911-2921. PubMed ID: 35641256
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
Doudican NA; Orlow SJ
Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
[TBL] [Abstract][Full Text] [Related]
6. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
7. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
8. PDE8A runs interference to limit PKA inhibition of Raf-1.
Maurice DH
Proc Natl Acad Sci U S A; 2013 Apr; 110(16):6248-9. PubMed ID: 23550163
[No Abstract] [Full Text] [Related]
9. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.
Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
[TBL] [Abstract][Full Text] [Related]
10. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
14. All-
Kim G; Bhattarai PY; Oh CH; Choi HS
Anticancer Res; 2019 Dec; 39(12):6537-6546. PubMed ID: 31810919
[TBL] [Abstract][Full Text] [Related]
15. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
16. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
Fallahi-Sichani M; Becker V; Izar B; Baker GJ; Lin JR; Boswell SA; Shah P; Rotem A; Garraway LA; Sorger PK
Mol Syst Biol; 2017 Jan; 13(1):905. PubMed ID: 28069687
[TBL] [Abstract][Full Text] [Related]
17. B-RAF is a therapeutic target in melanoma.
Karasarides M; Chiloeches A; Hayward R; Niculescu-Duvaz D; Scanlon I; Friedlos F; Ogilvie L; Hedley D; Martin J; Marshall CJ; Springer CJ; Marais R
Oncogene; 2004 Aug; 23(37):6292-8. PubMed ID: 15208680
[TBL] [Abstract][Full Text] [Related]
18. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
[TBL] [Abstract][Full Text] [Related]
19. METTL3 induces PLX4032 resistance in melanoma by promoting m
Bhattarai PY; Kim G; Poudel M; Lim SC; Choi HS
Cancer Lett; 2021 Dec; 522():44-56. PubMed ID: 34530048
[TBL] [Abstract][Full Text] [Related]
20. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]